First Patient Dosed in NefIgArd Open Label Extension Study

Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the first patient has been dosed in the global open-label extension (OLE) of the Phase 3 NefIgArd study. OLE offers a 9-month treatment with Nefecon to all qualifying patients who have completed the NefIgArd study and will evaluate the efficacy and safety of Nefecon treatment in patients with IgA Nephropathy (IgAN).

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...